Daily Pulse: China Expects Publicly Available COVID-19 Vaccines in November

4 ratings

Wu GuiZhen, the chief biosafety expert of the Chinese Center for Disease Control and Prevention (China CDC), said citizens may be able to receive COVID-19 vaccine injections this coming November. Among the nine vaccine candidates globally that have started phase III clinical trials, five of these are from Chinese companies, including one jointly developed with other countries. In the finance sector, Alibaba-backed [BABA:US] Ant Group reportedly is looking to receive a listings hearing with HKEX [0388:HK] in the next week. The firm intends to debut on SSE STAR Market and HKEX concurrently. A-share markets fell today. SHCOMP went down 0.36% to 3,283.92, SICOM tumbled 1.01% to 13,011.28, and CSI 300 decreased 0.66% to 4,657.36. ChiNext Price Index dropped 1.55% to 2,554.80. The Hang Seng Index edged down 0.05% today to 24,720.66.

Xiamen Bank intends to issue 264m shares for its IPO on SSE at a price of RMB6.71 per share, representing 10% of its post-issuance equity. The company has passed a listings hearing on July 16 and it plans to start share subscriptions on October 13. In the technology sector, Semiconductor Manufacturing International Corp (SMIC) [0981:HK] has applied for permission with the US to continue supplying chips to Huawei. The Trump administration’s May order went into effect on September 15, effectively cutting off chip supplies that contain US technologies to Huawei.

Related Tags
Topics Entities
Health Medical PharmaBusiness FinanceHong Kong Exchanges And ClearingSemiconductor Manufacturing International CorporationHuaweiCOVID 19 VaccineHang Seng IndexChiNextVaccine